| Panel Member | Clinical Research Support/Data Safety Monitoring Board | Scientific Advisory Boards, Consultant, or Expert Witness | Promotional Advisory Boards, Consultant, or Speakers Bureau | Date Completed |
|---|---|---|---|---|
| Douglas W. Ball, MD | Eisai Inc.; Exelixis Inc.; and Roche USA | Exelixis Inc. | None | 12/7/11 |
| Naifa Lamki Busaidy, MD | Bayer HealthCare | Bayer HealthCare | None | 11/12/14 |
| David Byrd, MD | None | None | None | 11/10/14 |
| Glenda Callender, MD | None | None | None | 9/20/14 |
| Paxton Dickson, MD | None | None | None | 3/1/15 |
| Quan-Yang Duh, MD | None | None | None | 9/23/14 |
| Hormoz Ehya, MD | None | Eli Lilly and Company | None | 10/29/14 |
| Robert I. Haddad, MD | Boehringer Ingelheim GmbH; Bristol-Myers Squibb Company; Celgene Corporation; Merck & Co., Inc.; and VentiRx Pharmaceuticals, Inc. | Bristol-Myers Squibb Company; Celgene Corporation; Eisai Inc.; and Merck & Co., Inc. | None | 2/27/15 |
| Megan Haymart, MD | National Cancer Institute | None | None | 8/10/15 |
| Carl Hoh, MD | None | None | None | 10/3/13 |
| Jason P. Hunt, MD | None | None | None | 11/5/14 |
| Andrei Iagaru, MD | General Electric | Bayer HealthCare | None | 10/28/14 |
| Fouad Kandeel, MD, PhD | None | None | None | 2/25/15 |
| Peter Kopp, MDa | None | None | None | 5/8/14 |
| Dominick M. Lamonica, MD | None | None | None | 2/23/15 |
| William M. Lydiatt, MD | None | None | None | 2/26/15 |
| Judith C. McCaffrey, MD | None | None | None | 2/26/15 |
| Jeffrey F. Moley, MD | AstraZeneca Pharmaceuticals LP; and Exelixis Inc. | Exelixis Inc. | None | 4/6/15 |
| Lee Parks, MD | AstraZeneca Pharmaceuticals LP | None | None | 2/24/15 |
| Christopher D. Raeburn, MD | None | None | None | 10/14/14 |
| John A. Ridge, MD, PhD | None | None | None | 2/26/15 |
| Matthew D. Ringel, MDa | National Cancer Institute | None | None | 9/30/14 |
| Randall P. Scheri, MD | None | None | None | 10/23/14 |
| Jatin P. Shah, MD, PhD | None | None | None | 7/1/15 |
| Robert C. Smallridge, MDa | AstraZeneca Pharmaceuticals LP; and GlaxoSmithKline | None | None | 10/27/14 |
| Cord Sturgeon, MD | None | None | None | 2/25/15 |
| Thomas N. Wang, MD, PhD | None | None | None | 11/6/14 |
| Lori J. Wirth, MD | AstraZeneca Pharmaceuticals LP; Eisai Inc.; Exelixis Inc.;Genentech, Inc.; and Novartis Pharmaceuticals Corporation | AstraZeneca Pharmaceuticals LP; and Eisai Inc. | AstraZeneca Pharmaceuticals LP; and Eisai Inc. | 12/4/14 |
a
The following of disclosed that they have an Employment/Governing Board, Patent, Equity, or Royalty conflict: Peter Kopp, MD: American Thyroid Association; Editor in Chief of Thyroid. Official Journal American Thyroid Association Matthew Ringel, MD: International Thyroid Oncology Group; The Endocrine Society Robert C. Smallridge, MD: American Thyroid Association
The NCCN Guidelines Staff have no conflicts to disclose.